Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Bristol-Myers Squibb

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb

4Q Revenues: $5 billion (-3%)

4Q Earnings: $499 million (+259%)

FY Revenues: $19 billion (-1%)

FY Earnings: $3 billion (+25%)

Comments: Orencia was approved for the treatment of RA symptoms in the quarter. Worldwide pharmaceutical sales decreased 3% to $4 billion in the quarter. Sales of Plavix increased 11% to $1 billion in the quarter; sales of Avapro/Avalide increased 7% to $277 million in the quarter; total revenue for Abilify increased 17% to $224 million. R&D spend was up 14% in the quarter to $775 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters